TICKERNERD
Menu
NSRXNSRXHealthcare · Drug Manufacturers - General

NSRX Stock Forecast: Nasus Pharma Ltd. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$3.44
−2.55% on the day

The 2 Wall Street analysts covering Nasus Pharma Ltd. hold a median 12-month price target of $19 — +452.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$41.3M
Ticker Nerd rank
17 / 100
Median analyst target
$19
Analysts covering
2
Total return, dividends reinvested
1W
−5.8%
1M
−14.0%
YTD
−62.4%
1Y
−57.1%
From 52W high
−62.4%
From 52W low
+71.1%
$2.01
$9.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NSRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nasus Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
84
Issuance
59
Revisions
52
Value
43
Momentum
20
Accruals
17
Quality
10
Volatility
10
Growth
8

Size (84): Smaller than most of the companies we track.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NSRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NSRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26NSRXHigh $22Median $19Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $18Median $19High $22

The green dot is the last close — the median target sits +452.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Mar 2026CitizensMaintainsMarket Outperform—
18 Dec 2025CitizensInitiatesMarket Outperform—
29 Sept 2025Laidlaw & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NSRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NSRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, Nasus Pharma Ltd. returned −57.1% against +17.8% for the S&P 500, dividends included.

NSRX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26NSRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NSRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Nasus Pharma Ltd. (NSRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.8×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
3.8×

Cheaper than 27% of US stocks

EV / EBITDA
−7.5×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−316.0%

Higher than 5% of US stocks

Return on assets
−96.7%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nasus Pharma Ltd. (NSRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nasus Pharma Ltd. has a market value of $41.3M and an enterprise value of $29.6M.

  • Shares outstanding: 11.7M.

  • Trailing P/E: −4.8×; forward P/E: −3.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Nasus Pharma Ltd. employs 7 people.

market figures as at 21 Sept 2026

Data provided by Twelve Data

Peers

NSRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
NSRXNasus Pharma Ltd.$41.3M
17
SCLXScilex Holding Co.$35.5M
13
MIRAMIRA Pharmaceuticals, Inc.$34.9M
27
MGXMetagenomi Therapeutics, Inc.*$41.3M
29
ONMDOneMedNet Corp.*$41.5M
15
VERUVeru, Inc.*$41.1M
33
ZYBTZhengye Biotechnology Holding Ltd.*$40.7M
48

* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nasus Pharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NSRX news & analysis

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

GlobeNewsWire · 14 Sept 2026positive

Nasus Pharma announced that the FDA has cleared the initiation of a clinical study of NS002, its investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen for treating anaphylaxis. The study will compare self-administration with administration by a healthcare professional, with a pivotal study planned for the fourth quarter of 2026 and topline data expected in the first quarter of 2027.

Why it matters — This FDA clearance advances NS002, a key product in Nasus Pharma's pipeline, toward pivotal clinical development for anaphylaxis treatment.

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Nasus Pharma announced that its management team will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026 in New York, NY at the Lotte New York Palace hotel.

Why it matters — Investors following NSRX may view this conference presence as an opportunity for the company to present its intranasal product pipeline and engage with the investment community.

Nasus Pharma Announces Transition of Chief Financial Officer

GlobeNewsWire · 19 Aug 2026neutral

Nasus Pharma announced that Chief Financial Officer Eyal Rubin is leaving the company to pursue a new opportunity outside the life science industry. The departure was disclosed via a GlobeNewswire release from the company's Tel Aviv headquarters.

Why it matters — A change in the CFO role is a notable leadership transition for a clinical-stage company that NSRX shareholders and followers would want to monitor.

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

GlobeNewsWire · 17 Aug 2026positive

Nasus Pharma announced its financial results for the six months ending June 30, 2026, and provided a corporate update. The company also reported the appointment of pharma industry veteran Brendan O'Grady as Chief Executive Officer and stated it remains on track to advance its clinical programs toward key second half 2026 milestones.

Why it matters — For NSRX watchers, this update signals new executive leadership and reaffirms the company's expected progress on its clinical programs heading into key second-half 2026 milestones.

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth

GlobeNewsWire · 28 July 2026positive

Nasus Pharma announced the appointment of Brendan P. O'Grady as its new Chief Executive Officer, effective July 27, 2026, succeeding Dan Teleman. O'Grady is tasked with leading the Company's next growth phase, including commercializing NS002 and advancing its intranasal technology platform.

Why it matters — A leadership change at the CEO level signals a strategic shift for Nasus Pharma as it aims to commercialize its lead candidate NS002 and build value around its Nasax® platform, which could affect the company's direction and milestones for investors.

FAQ

Frequently asked questions about NSRX stock

What is the NSRX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Nasus Pharma Ltd. have a median 12-month price target of $19, with estimates ranging from $18 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NSRX stock a buy right now?

Of the 2 analysts covering Nasus Pharma Ltd., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nasus Pharma Ltd. 17 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NSRX?

As at 19 Sept 2026, Nasus Pharma Ltd. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).

Will NSRX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +452.3% from the last close, and Ticker Nerd's factor model ranks Nasus Pharma Ltd. 17 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NSRX stock forecast for 2030?

No analyst covering Nasus Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NSRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $22 over the next 12 months.

How has NSRX stock performed over the past year?

Nasus Pharma Ltd. returned -57.1% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nasus Pharma Ltd. do?

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing intranasal medicines for emergency medical conditions.

What is the latest news on NSRX?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis". Nasus Pharma announced that the FDA has cleared the initiation of a clinical study of NS002, its investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen for treating anaphylaxis. The study will compare self-administration with administration by a healthcare professional, with a pivotal study planned for the fourth quarter of 2026 and topline data expected in the first quarter of 2027.

Company

About Nasus Pharma Ltd.

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing intranasal medicines for emergency medical conditions. The company’s current portfolio centers on powder-based intranasal drug delivery products designed to address acute, time-sensitive situations such as severe allergic reactions and opioid overdose. Its lead programs include intranasal epinephrine and intranasal naloxone, both aimed at delivering medication through a needle-free format that is practical for urgent community use. Nasus Pharma Ltd. operates in the healthcare and pharmaceuticals sector, with its work positioned at the intersection of emergency treatment and innovative drug delivery technology. Based in Tel Aviv, Israel, the company’s business today is concentrated on advancing intranasal therapies that support rapid administration in critical care settings and public health response scenarios.

CEO Mr. Dan Teleman MBA M.Sc. · 7 employees · Israel · https://www.nasuspharma.com